Moolec Science (MLEC)
NASDAQ:MLEC
Want to see MLEC full AI Analyst Report?
Top Page
Moolec Science
(NASDAQ:MLEC)
Select Model
Select Model
Rating:46Neutral
Price Target:
$7.50
▼(-16.01% Downside)
Action:Reiterated
Date:05/01/26
The score is held down primarily by weak financial health—large losses, continued cash burn, and a materially weakened capital structure with negative equity and elevated debt. Technicals are moderately supportive with improving intermediate momentum, but valuation remains constrained by unprofitability and no dividend support.
Positive Factors
Commercial traction and improving gross margins
A very large revenue ramp and a jump to ~34% gross margin indicate the company is moving from R&D into commercial supply. Sustained ingredient sales and improving unit economics provide a durable path to scale operations and margin expansion if topline growth continues and processing is optimized.
Negative Factors
Weakened balance sheet and high leverage
Negative equity and near-$247M debt leave the company highly leveraged, constraining financial flexibility. Even with later equity actions, elevated borrowings raise refinancing and covenant risk and limit capacity to fund commercialization or absorb setbacks without dilutive or costly financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial traction and improving gross margins
A very large revenue ramp and a jump to ~34% gross margin indicate the company is moving from R&D into commercial supply. Sustained ingredient sales and improving unit economics provide a durable path to scale operations and margin expansion if topline growth continues and processing is optimized.
Read all positive factors
Moolec Science (MLEC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.35M
Dividend YieldN/A
Average Volume (3M)209.37K
Price to Earnings (P/E)―
Beta (1Y)-0.20
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees52
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding726,118
10 Day Avg. Volume506,476
30 Day Avg. Volume209,369
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.62
Price to Sales (P/S)0.12
P/FCF Ratio-1.35
Enterprise Value/Market Cap47.08
Enterprise Value/Revenue32.14
Enterprise Value/Gross Profit-393.68
Enterprise Value/Ebitda-48.30
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Moolec Science Business Overview & Revenue Model
Company Description
Moolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. The company's product portfolio and pipeline leverage th...
How the Company Makes Money
Moolec Science makes money primarily by developing and commercializing genetically engineered crops that produce value-added food ingredients, then monetizing the resulting ingredients and/or the underlying technology. Key revenue streams include:...
Moolec Science Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
14
Very Negative
Cash Flow
22
Negative
| Breakdown | TTM | Sep 2024 | Sep 2023 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.83M | 333.61M | 5.63M | 905.05K | 0.00 | 0.00 |
| Gross Profit | -639.50K | 114.01M | 472.58K | -143.31K | 0.00 | 0.00 |
| EBITDA | -5.21M | -69.01M | -6.16M | -51.74M | -3.65M | -13.80K |
| Net Income | -8.28M | -111.46M | -7.31M | -51.79M | -4.53M | -13.80K |
Balance Sheet | ||||||
| Total Assets | 31.38M | 204.71M | 34.79M | 24.05M | 5.69M | 138.59M |
| Cash, Cash Equivalents and Short-Term Investments | 1.93M | 9.02M | 5.39M | 2.83M | 1.08M | 337.60K |
| Total Debt | 22.09M | 246.88M | 14.68M | 2.65M | 125.00K | 125.00K |
| Total Liabilities | 28.58M | 287.58M | 27.97M | 13.95M | 4.09M | 4.51M |
| Stockholders Equity | 2.80M | -65.97M | 6.82M | 10.11M | 1.60M | 134.08M |
Cash Flow | ||||||
| Free Cash Flow | -6.12M | -30.10M | -9.49M | -7.69M | -1.89M | -8.80K |
| Operating Cash Flow | -5.70M | -24.45M | -9.33M | -7.51M | -1.89M | -8.80K |
| Investing Cash Flow | -270.17K | -35.99M | 134.87K | -2.34M | -138.00M | 0.00 |
| Financing Cash Flow | 5.95M | 13.07M | 11.71M | 11.28M | 139.05M | 14.49K |
Moolec Science Technical Analysis
Negative
8.93
Price Trends
8.34
Negative
8.05
Negative
11.49
Negative
Market Momentum
-0.20
Positive
42.42
Neutral
7.65
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLEC, the sentiment is Negative. The current price of 8.93 is above the 20-day moving average (MA) of 8.72, above the 50-day MA of 8.34, and below the 200-day MA of 11.49, indicating a bearish trend. The MACD of -0.20 indicates Positive momentum. The RSI at 42.42 is Neutral, neither overbought nor oversold. The STOCH value of 7.65 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MLEC.
Moolec Science Risk Analysis
Moolec Science disclosed 3 risk factors in its most recent earnings report. Moolec Science reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Auditors Q2, 2024
2.
Directors and Senior Management Q2, 2024
3.
Advisors Q2, 2024
Moolec Science Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $5.35M | -0.37 | -174.68% | ― | ― | ― | |
43 Neutral | $3.55M | -0.21 | 261.84% | ― | -35.62% | 70.55% | |
42 Neutral | $4.75M | -0.26 | -386.72% | ― | -24.36% | 47.35% | |
| ― | $13.68M | -0.51 | -24.80% | ― | -4.23% | -17.96% | |
42 Neutral | $3.71M | -0.15 | ― | ― | ― | 76.55% |
* Healthcare Sector Average
MLEC
Moolec Science
7.77
-125.73
-94.18%
AIM
AIM ImmunoTech
0.24
-8.24
-97.21%
ENSC
Ensysce Biosciences
0.32
-1.88
-85.55%
CYCN
Cyclerion Therapeutics
3.18
-0.09
-2.75%
CLDI
Calidi Biotherapeutics
0.18
-4.75
-96.44%
Moolec Science Corporate Events
Moolec Science Shareholders Approve 2025 Accounts and Board Slate at May 13 AGM
May 14, 2026
Moolec Science SA held its virtual Annual General Meeting of shareholders on May 13, 2026, with 71.24% of the 2,080,437 ordinary shares entitled to vote represented, establishing a valid quorum. Shareholders approved the consolidated financial sta...
Moolec Science Swings to Profit on Subsidiary Deconsolidation in Latest Interim Results
May 14, 2026
On May 13, 2026, Moolec Science SA filed a Form 6-K with the U.S. Securities and Exchange Commission for the month of May 2026, incorporating by reference unaudited interim condensed consolidated financial statements. The filing covers the company...
Moolec Science Regains Nasdaq Compliance After Strengthening Equity Base
May 13, 2026
On May 13, 2026, Moolec Science SA announced that it has regained compliance with all Nasdaq Capital Market continued listing requirements related to minimum stockholders’ equity within the remediation period granted by a Nasdaq Hearings Pan...
Moolec Science Sets May 13, 2026 Virtual AGM to Approve 2025 Results and Board Slate
Apr 15, 2026
Moolec Science SA has filed a Form 6-K dated April 15, 2026, announcing that it will hold its annual general meeting of shareholders virtually on May 13, 2026, at 9:00 a.m. Eastern Time. The meeting will be accessible to registered and beneficial ...
Moolec Science Gains New Controlling Shareholder as AIGC Takes 65% Stake
Apr 2, 2026
On April 1, 2026, Agriculture Investment Group Corp. became the controlling shareholder of Moolec Science SA, acquiring 65.1% of the company’s outstanding shares through a partial conversion of preference shares into ordinary shares. The tra...
Moolec Science Overhauls Board With New Quality-Focused Director
Feb 26, 2026
On February 25, 2025, Moolec Science SA, a plant- and microbe-based protein innovator for the global food industry, announced a reshaping of its board of directors. The company appointed U.S.-based quality and operations veteran Daniel Core to its...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.